Treatment evaluation of liraglutide in Type 2 Diabetes

Expert Opinion on Biological Therapy

Volumn 12, Issue 11, 2012, Pages 1551-1556

  Kela, Ram ^b   Davies, Melanie J ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b Bassetlaw District General Hospital   (United Kingdom)

Author keywords

Cardiology; GLP 1 receptor; Liraglutide; Renal impairment

Indexed keywords

EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; HEMOGLOBIN A1C; INSULIN DERIVATIVE; INSULIN DETEMIR; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; ROSIGLITAZONE; SITAGLIPTIN; ANTIDIABETIC AGENT; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL;

ADD ON THERAPY; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HUMAN; HYPOGLYCEMIA; KIDNEY DISEASE; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; DRUG SCREENING; GLUCOSE BLOOD LEVEL; METABOLISM; PROCEDURES; TREATMENT OUTCOME;

ANIMALS; BLOOD GLUCOSE; CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DRUG EVALUATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; RECEPTORS, GLUCAGON; TREATMENT OUTCOME;

EID: 84867319620     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.716823     Document Type: Review

References (23)

1. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359:824-30
2. Steensgaard D, Thomsen J, Olsen H, Knudsen LB. The molecular basis for the delayed absorption of the once-daily human GLP-1 analogue, liraglutide. Diabetes 2008;57(Suppl 1):A164
3. Agerso H, Jensen LB, Elbrond B, et al. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP- 1 derivative, in healthy men. Diabetologia 2002;45:195-202
4. Rosenstock J, Gumprecht J, Szyprowska E, et al. Pharmacokinetics of liraglutide vs exenatide in type 2 diabetes: sustained vs fluctuating concentrations over 24 h. Diabetes 2009;58(Suppl 1):A150
5. Vilsbøll T, Zdravkovic M, Le Thi T, et al. liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10
6. National Institute of health and Clinical Excellence. Liraglutide for treatment of type 2 diabetes mellitus- NICE technology appraisal guidance 203, October 2010
7. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
8. Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD- 3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
9. Marre M, Shaw J, Brandle M, et al.Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78
10. Nauck M, Frid A, Hermansen K, et al. Efficacy and Safety comparison of liraglutide, glimepiride, and placebo, All in combination with metformin, in type 2 diabetes. Diabetes Care 2009;32:84-90
11. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55
12. Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009; 32:1224-30
13. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56
14. Devries JH, Bain SC, Rodbard HW, et al. Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets. Diabetes Care 2012; 35(7):1446-54
15. Holst J, Nauck M, Brett J, et al. Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomised clinical trials. Diabetologia 2009;52(Suppl 1):S288
16. Fonseca V, Madsbad S, Falahati A, et al. Once-daily human GLP-1 analog liraglutide reduces systolic blood pressure - a meta-analysis of 6 clinical trials. Diabetes 2009;58(Suppl 1):A146
17. Chatterjee DJ, Khutoryansky N, Zdravkovic M, et al. Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;49:1353-62
18. Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER). ClinicalTrials. gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01179048?term= LEADER&rank=3 [Accessed 15 January 2012]
19. Davidson J, Brett J, Falahati A, Scott D. Mild renal impairment has no effect on the efficacy and safety of liraglutide. Endocr Pract 2011;17(3):345-55
20. Knudsen LB, Madsen LW, Andersen S, et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151:1473-86
21. Hegedus L, Moses AC, Zdravkovic M, et al. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011; Mar 96(3):853-60
22. Liraglutide US Prescribing Information. Available from: http://www.victoza.com/pdf/Victoza-ComboPI-5.24.pdf [Accessed 22 July 2011]
23. Garg R, Chen W, Pendergrass M. Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010; 33(11):2349-54